Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 139,229 182,993 316,353 638,922
Total Sell Value $12,316,080 $16,513,389 $28,948,007 $60,375,372
Total People Sold 5 5 6 8
Total Sell Transactions 11 15 24 57
End Date 2024-01-25 2023-10-24 2023-04-25 2022-04-25

   
Records found: 1213
  Page 9 of 49  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Baffi Robert EVP, Technical Operations   •       –      –    2013-03-18 4 OE $14.39 $287,800 D/D 20,000 72,350     -
   Grey Michael G Director   –       •      –    2013-03-06 4 S $60.61 $909,135 D/D (15,000) 19,650     -
   Davis George Eric SVP, General Counsel   •       –      –    2013-03-04 4 S $60.18 $240,724 D/D (4,000) 46,200     -
   Davis George Eric SVP, General Counsel   •       –      –    2013-03-04 4 OE $17.86 $71,440 D/D 4,000 50,200     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2013-03-04 4 AS $60.00 $240,000 D/D (4,000) 10,570     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2013-03-04 4 OE $21.51 $86,040 D/D 4,000 14,570     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-03-04 4 AS $60.00 $300,000 I/I (5,000) 13,545     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-03-04 4 OE $12.99 $64,950 I/I 5,000 23,545     -
   Grey Michael G Director   –       •      –    2013-03-03 4 OE $14.39 $215,850 D/D 15,000 34,650     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-03-01 4 AS $59.14 $59,140 D/D (1,000) 119,401     -
   Mueller Brian VP, Corporate Controller   •       –      –    2013-03-01 4 S $59.81 $120,510 D/D (2,015) 13,279     -
   Mueller Brian VP, Corporate Controller   •       –      –    2013-03-01 4 S $59.74 $300,067 D/D (5,023) 15,294     -
   Mueller Brian VP, Corporate Controller   •       –      –    2013-03-01 4 OE $14.39 $91,464 D/D 5,023 20,317     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2013-03-01 4 D $59.61 $113,736 D/D (1,908) 44,589     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-02-28 4 AS $58.00 $290,000 I/I (5,000) 18,545     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-02-28 4 OE $12.99 $64,950 I/I 5,000 18,545     -
   Davis George Eric SVP, General Counsel   •       –      –    2013-02-27 4 S $56.90 $455,186 D/D (8,000) 46,200     -
   Davis George Eric SVP, General Counsel   •       –      –    2013-02-27 4 OE $14.39 $125,884 D/D 8,000 54,200     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-02-27 4 S $56.46 $84,683 D/D (1,500) 120,401     -
   Lewis Alan Director   –       •      –    2013-02-27 4 S $56.57 $1,272,762 D/D (22,500) 15,900     -
   Lewis Alan Director   –       •      –    2013-02-27 4 OE $14.39 $558,675 D/D 22,500 38,400     -
   Lapalme Pierre Director   –       •      –    2013-02-26 4 S $55.34 $1,654,798 D/D (29,900) 24,650     -
   Lapalme Pierre Director   –       •      –    2013-02-26 4 OE $8.47 $306,853 D/D 29,900 54,550     -
   Wood Mark VP, Human Resources   •       –      –    2013-02-22 4 AS $55.00 $171,344 D/D (3,103) 23,245     -
   Wood Mark VP, Human Resources   •       –      –    2013-02-22 4 OE $14.39 $72,412 D/D 3,103 26,348     -
  1213 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 9 of 49
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us